<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-42051" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Migraine Surgical Interventions</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bajaj</surname>
            <given-names>Jitin</given-names>
          </name>
          <aff>NSCB Govt. Medical College, Jabalpur</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Munakomi</surname>
            <given-names>Sunil</given-names>
          </name>
          <aff>Kathmandu University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jitin Bajaj declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sunil Munakomi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-42051.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Migraines are a common primary neurologic headache that predominantly occurs in the working-age adult. Migraine attacks are frequently triggered by bright light, hunger, and loud noise. It is theorized that this causes contraction of facial and scalp muscles leading to irritation of the susceptible peripheral branches of the trigeminal nerves which creates a wave of spreading pain to the whole of the cranium. This peripheral theory of migraine is supported by pain relief that many patients report with Botulinum toxins or local nerve blocks. This activity describes the indications for surgical management of chronic migraines. It highlights the role of an interprofessional team comprised of neurologists, neurosurgeons, plastic surgeons, and psychologists, in caring for patients with this ailment.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of migraines.</p></list-item><list-item><p>Review common physical exam findings of a patient with a migraine.</p></list-item><list-item><p>Explain how surgical intervention can help stop migraines.</p></list-item><list-item><p>Outline a well-coordinated interprofessional team approach to provide effective care to patients affected by chronic migraines.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=42051&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=42051">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-42051.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Migraine is a primary neurologic headache, often accompanied by nausea, vomiting, photophobia, phonophobia, or vertigo, and may present with or without aura.<xref ref-type="bibr" rid="article-42051.r1">[1]</xref>&#x000a0;It is prevalent in 11.7% of Americans with 17.1% in women, and 5.6% in men.<xref ref-type="bibr" rid="article-42051.r2">[2]</xref>&#x000a0;Migraine can be acute or chronic. Treatment of this condition includes beta-blockers, anticonvulsants, calcium channel blockers, tricyclic antidepressants, non-steroidal anti-inflammatory drugs, among others.<xref ref-type="bibr" rid="article-42051.r3">[3]</xref>&#x000a0;Migraine surgery is indicated when the condition is refractory to medical management.</p>
        <p>Chronic migraine is&#x000a0;defined by the International Headache Society classification of headache disorders (ICHD-3). It is described as:</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache occurring on &#x02265;15&#x02009;days/month</p>
          </list-item>
          <list-item>
            <p>Duration &#x0003e;&#x02009;3&#x02009;months</p>
          </list-item>
          <list-item>
            <p>Having features of migraine on &#x02265;8&#x02009;days/month</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-42051.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>There are several theories for migraine generation. Previously, vasodilation of the cerebral vasculature was proposed as the mechanism, but it has been refuted by several experiments that showed an absence of migraine with the vasoactive intestinal peptide that increases the blood flow.<xref ref-type="bibr" rid="article-42051.r4">[4]</xref>&#x000a0;Similarly, the drugs precipitating migraine, like sildenafil do not cause sustained vascular changes.<xref ref-type="bibr" rid="article-42051.r5">[5]</xref>&#x000a0;There is&#x000a0;evidence to show cortical and brainstem hyperexcitability in a headache,<xref ref-type="bibr" rid="article-42051.r6">[6]</xref><xref ref-type="bibr" rid="article-42051.r7">[7]</xref>&#x000a0;and cortical spreading depression are responsible for the aura.<xref ref-type="bibr" rid="article-42051.r8">[8]</xref>&#x000a0;There is evidence&#x000a0;that&#x000a0;shows trigeminal afferents projecting to meninges and releasing pain mediators like substance P, calcitonin gene-related peptide, and neurokinin A, thus causing a vicious cycle of sterile meningitis.<xref ref-type="bibr" rid="article-42051.r9">[9]</xref>&#x000a0;The strongest clinical evidence&#x000a0;points toward the peripheral origin of a migraine. This is supported by the beneficial effect of Botulinum toxin and peripheral neurolysis for a chronic migraine, which is detailed in the following paragraphs.</p>
        <p>Migraine surgery focuses on the neurolysis of sensory branches of trigeminal and occipital nerves supplying the face and back of the head. These nerves include supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, and greater and lesser occipital nerves. Sometimes, the pain is also due to hypertrophic nasal turbinates or deviated nasal septum irritating branches of trigeminal nerves.</p>
      </sec>
      <sec id="article-42051.s4" sec-type="Indications">
        <title>Indications</title>
        <p>Migraine surgery is indicated when the disease is not controlled by conservative measures, which include medicines and behavioral therapy.</p>
      </sec>
      <sec id="article-42051.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>A confirmed psychiatric disease is a relative contraindication.</p>
      </sec>
      <sec id="article-42051.s6" sec-type="Personnel">
        <title>Personnel</title>
        <p>A neurologist should initially evaluate all cases.</p>
      </sec>
      <sec id="article-42051.s7" sec-type="Preparation">
        <title>Preparation</title>
        <p>The assessment of migraine severity can be done through several scales, of which the most commonly used is the Migraine Disability Assessment Questionnaire (MIDAS).<xref ref-type="bibr" rid="article-42051.r10">[10]</xref>&#x000a0;In this, 0 to 5 score is labeled as MIDAS grade I (little or no disability), 6 to 10 as MIDAS grade II (mild disability), 11 to 20 as MIDAS grade III (moderate disability), 21 and higher as MIDAS grade IV (severe disability).</p>
        <p>The initial treatment of a migraine is with drugs and behavioral methods, but often, patients develop refractoriness to these therapies.<xref ref-type="bibr" rid="article-42051.r11">[11]</xref><xref ref-type="bibr" rid="article-42051.r12">[12]</xref>&#x000a0;ICHD-3 beta has amended the definition of a refractory migraine as along with existent criteria, monthly migraine headaches of at least 8, with 15 or more headache days a month. A flowchart showing a management paradigm is shown in Figure 1.</p>
        <p>When there is suspicion of a rhinogenic headache, the clinician can order a computed tomography (CT) scan of the nose and paranasal sinuses.</p>
      </sec>
      <sec id="article-42051.s8" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>
<bold>Botulinum Toxin</bold>
</p>
        <p>Botulinum toxin&#x000a0;has to be instilled into pericranial muscles at multiple sites according to pain. The safe and effective dose is 25 units in total after mixing with normal saline. This can be divided into 3&#x000a0;units&#x000a0;for temporalis each side (total 6&#x000a0;units), 2.5&#x000a0;units&#x000a0;at 4 frontalis sites (5&#x000a0;units&#x000a0;unilaterally; 10&#x000a0;units&#x000a0;for both sides), 3&#x000a0;units&#x000a0;at corrugators on each side (total 6&#x000a0;units), and 3&#x000a0;units&#x000a0;for procerus in the midline.<xref ref-type="bibr" rid="article-42051.r13">[13]</xref>&#x000a0;For occipital headaches, one can instill about 12.5 to 50 units on each side of the midline in the region of greater and lesser occipital nerves. Pain relief for 6 to 12 weeks indicates an appropriate candidate for the surgery.</p>
        <p><bold>Peripheral Neurolysis</bold>&#x000a0;&#x000a0;</p>
        <p>Frontal headache: An eyelid incision is used. The orbital septum is retracted caudally and the orbicularis retracted cranially. The corrugator supercilii&#x000a0;and depressor supercilii are resected, and the nerves are freed. Both supraorbital and supratrochlear vessels are sacrificed, and the supraorbital foramen is unroofed. The space made is filled with the medial orbital fat and fixed with 6-0 polyglactin 910. The incisions are then closed with 6-0 nylon sutures. This can be done bilaterally.<xref ref-type="bibr" rid="article-42051.r14">[14]</xref></p>
        <p>Anterior Temporal headache: The procedure described is cutting of the zygomaticotemporal nerve. For a frontotemporal headache, it is combined with the procedure for frontal headaches by making 2 incisions, one in the upper tarsal crease and another at the superior temporal line.<xref ref-type="bibr" rid="article-42051.r15">[15]</xref>&#x000a0;These can also be done endoscopically.<xref ref-type="bibr" rid="article-42051.r14">[14]</xref>&#x000a0;The zygomaticotemporal nerve&#x000a0;is found about 16-mm lateral to the lateral canthus and 6-mm cranial to it. A small incision of size 2 cm is made at this point and dissection is done in between the 2 layers of temporalis fascia. The nerve can be found at the lateral margin of orbit. It is cut&#x000a0;and the end is buried deep into the muscle. The closure is done in layers.</p>
        <p>Posterior temporal headache: For this, the auriculotemporal nerve is the culprit. The incision is made at the base of side burn of a size of 2 cm. The nerve along with the superficial temporal vessels are identified. The vessels are sacrificed. The nerve is isolated for about 1 to 2 cm, is cut, and then buried in the temporalis muscle. The incision is closed in layers.</p>
        <p>Occipital&#x000a0;headache:&#x000a0;In case of an occipital migraine, occipital nerve neurolysis from semispinalis capitis muscle can be performed.<xref ref-type="bibr" rid="article-42051.r16">[16]</xref>&#x000a0;For diffuse occipital region pain, one should perform greater occipital neurolysis. A midline incision is made from external occipital protuberance to the C2 spinous process. The trapezius fascia is cut about 1cm off midline. The trapezius fibers are split in line and dissection is performed below it to find the greater occipital nerve. The semispinalis capitis muscle around the nerve is transected to free the nerve. Similarly, the trapezius muscle and fascia over the nerve are removed. The procedure can be repeated on the opposite side also. A pedicled fat is taken from the overlying skin and inserted between the nerve and the muscle and sutured there to be held in place. The incision is then closed with nylon 3-0.</p>
        <p>For lateral occipital headache lesser occipital neurolysis or neurectomy can be performed. A 2-cm incision is made about 2 cm medial to the mastoid in the hairline. The thick temporal fascia is incised. The lesser occipital nerve is dissected out along with the vessel. The artery is coagulated and cut. The nerve is dissected out for about 1 to 2 cm, is cut and buried in the muscle. The incision is closed with nylon 3-0.</p>
        <p>Occipital neurolysis though has immediate relief but also has high chances of recurrence,<xref ref-type="bibr" rid="article-42051.r16">[16]</xref>&#x000a0;and in such cases, alternative options like neuromodulation can be tried.</p>
        <p>Rhinogenic headaches: If hypertrophied turbinates or deviated nasal septum is identified as the cause of headaches then turbinectomy or septoplasty is done in the standard manner. The&#x000a0;branches of the maxillary nerve through sphenopalatine ganglion mediate this type of headaches and botulinum toxin treatment is not effective in such patients.</p>
        <p>
<bold>Neuromodulation for Migraine</bold>
</p>
        <p>Neuromodulation is done when there is a failure of medical management, peripheral neurolysis is not feasible or has failed. The foremost option is occipital nerve stimulation (ONS). It is done by placing electrodes around cervical dorsal nerves in the suboccipital region and connecting them first to a trial stimulator, and if successful to a permanently implantable pulse generator. Other options of neuromodulation include sphenopalatine ganglion stimulation,<xref ref-type="bibr" rid="article-42051.r17">[17]</xref>&#x000a0;supraorbital nerve stimulation,<xref ref-type="bibr" rid="article-42051.r18">[18]</xref><xref ref-type="bibr" rid="article-42051.r19">[19]</xref>&#x000a0;and vagus nerve stimulation.<xref ref-type="bibr" rid="article-42051.r20">[20]</xref><xref ref-type="bibr" rid="article-42051.r21">[21]</xref>&#x000a0;Though these have proved their beneficial roles in initial studies, large controlled trials are needed.</p>
        <p>
<bold>Nerve Decompression</bold>
</p>
        <p>The decompression of the nerves in trigger site areas (frontal, temporal, occipital) by removing the surrounding tissues including muscles and blood vessels can be useful in patients with medically refractory chronic migraines.<xref ref-type="bibr" rid="article-42051.r22">[22]</xref></p>
      </sec>
      <sec id="article-42051.s9" sec-type="Complications">
        <title>Complications</title>
        <p>
<bold>Botulinum Toxin</bold>
</p>
        <p>One can have transient hollowness of muscles in which the drug is injected, especially the temporalis muscle. The incidence can be around 23%.<xref ref-type="bibr" rid="article-42051.r23">[23]</xref>&#x000a0;Other complications may be transient eyelid ptosis (when injected into the eyebrow muscles), or neck muscle weakness (when injected into the cervical region).</p>
        <p>
<bold>Peripheral Neurolysis/Neurectomy</bold>
</p>
        <p>Patients can have neuroma formation when a neurectomy is conducted. This can be prevented by burying the cut nerve end in the muscle. Infection, hemorrhage can be associated, but the incidence is low.&#x000a0;Temporary paresthesia and itching in the area of surgery can also be found.<xref ref-type="bibr" rid="article-42051.r24">[24]</xref></p>
        <p>
<bold>Turbinate Surgery</bold>
</p>
        <p>One can have postoperative epistaxis, sinusitis, nasal dryness, or septal deviation.<xref ref-type="bibr" rid="article-42051.r23">[23]</xref></p>
        <p>
<bold>Neuromodulation</bold>
</p>
        <p>Lead migration can occur if they are not anchored properly. Infection can be associated, these can generally be managed with antibiotics, and rarely require implant removal.</p>
      </sec>
      <sec id="article-42051.s10" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>A migraine is a common primary headache. A neurologist evaluates clinical features and the MIDAS score. Initial treatment is through medicines and behavioral therapy. Botulinum toxin is commonly used as a screening tool to identify the triggers. Peripheral neurolysis/neurectomy is an effective treatment for drug-refractory cases.</p>
      </sec>
      <sec id="article-42051.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The migraine patient should be&#x000a0;evaluated by an interprofessional team involving a neurologist, psychologist, psychiatrist, surgeon, specialty-trained neurology nurse, and allied health professionals. Appropriate case selection is necessary to have a successful&#x000a0;outcome of the surgery. A pharmacist should be involved in helping the team with pharmaceutical selection and maintenance. Nurses should assist in patient education before and after surgery. One should follow the methodology as given in the flowchart.</p>
        <p>
<bold>Botulinum Toxin</bold>
</p>
        <p>Botulinum toxin (BT)&#x000a0;is a toxin produced by <italic toggle="yes">Clostridium botulinum</italic>. It paralyzes muscles by inhibiting the release of acetylcholine from presynaptic terminals.&#x000a0;It has 8 subtypes: A through H, of which type A is safe and effective for therapeutic usage.<xref ref-type="bibr" rid="article-42051.r25">[25]</xref>&#x000a0;Justinus Kerner&#x000a0;discovered the idea of&#x000a0;botulinum toxin&#x000a0;to&#x000a0;be used as&#x000a0;a medical therapeutic, which he called&#x000a0;botulinum toxin&#x000a0;as "sausage poison." He did animal experiments and human experiments, including upon himself.<xref ref-type="bibr" rid="article-42051.r26">[26]</xref>&#x000a0;Scott initially used&#x000a0;botulinum toxin&#x000a0;for strabismus.<xref ref-type="bibr" rid="article-42051.r25">[25]</xref>&#x000a0;Thereafter, it was used in focal dystonia like blepharospasm,<xref ref-type="bibr" rid="article-42051.r27">[27]</xref><xref ref-type="bibr" rid="article-42051.r28">[28]</xref>&#x000a0;cervical dystonia,<xref ref-type="bibr" rid="article-42051.r29">[29]</xref><xref ref-type="bibr" rid="article-42051.r30">[30]</xref>&#x000a0;oromandibular dystonia,<xref ref-type="bibr" rid="article-42051.r31">[31]</xref>&#x000a0;laryngeal dystonia,<xref ref-type="bibr" rid="article-42051.r32">[32]</xref>&#x000a0;hemifacial spasm,<xref ref-type="bibr" rid="article-42051.r31">[31]</xref><xref ref-type="bibr" rid="article-42051.r33">[33]</xref>&#x000a0;writer&#x02019;s cramp,<xref ref-type="bibr" rid="article-42051.r34">[34]</xref>&#x000a0;spasticity, focal hyperhidrosis,<xref ref-type="bibr" rid="article-42051.r35">[35]</xref>&#x000a0;and to diagnose and treat trigger factors for migraine.<xref ref-type="bibr" rid="article-42051.r13">[13]</xref>&#x000a0;Botulinum toxin&#x000a0;reduces migraine frequency and severity by decreasing the irritation of peripheral nerves by paralyzing the triggers, i.e., muscles, and decreasing the inflammatory mediators.<xref ref-type="bibr" rid="article-42051.r36">[36]</xref>&#x000a0;Evidence, including double-blinded controlled trials, suggest more than a 50% reduction in frequency and severity of migraines at 3 months, with efficacy lasting 3 to 4 months,<xref ref-type="bibr" rid="article-42051.r13">[13]</xref><xref ref-type="bibr" rid="article-42051.r37">[37]</xref><xref ref-type="bibr" rid="article-42051.r38">[38]</xref>&#x000a0;but some other blind trials did not show or show only modest effects of&#x000a0;botulinum toxin&#x000a0;over placebo.<xref ref-type="bibr" rid="article-42051.r39">[39]</xref><xref ref-type="bibr" rid="article-42051.r40">[40]</xref></p>
        <p>Though&#x000a0;botulinum toxin&#x000a0;can be used short term as an acute and prophylactic treatment,<xref ref-type="bibr" rid="article-42051.r13">[13]</xref><xref ref-type="bibr" rid="article-42051.r37">[37]</xref>&#x000a0;its permanent use is difficult due to the development of resistance with time leading to a decrease in effect, and side-effects like muscle paralysis, muscle atrophy, and irritation, especially with higher doses.<xref ref-type="bibr" rid="article-42051.r13">[13]</xref><xref ref-type="bibr" rid="article-42051.r41">[41]</xref>&#x000a0;Therefore, some recommend only using it as a screening tool before the neurolysis.<xref ref-type="bibr" rid="article-42051.r42">[42]</xref></p>
        <p>
<bold>Peripheral Neurolysis</bold>
</p>
        <p>The beneficial effect of peripheral neurolysis of supratrochlear and supraorbital nerves on migraine was discovered when Guyuron found that his patients were relieved of a debilitating migraine&#x000a0;after brow lift surgery.<xref ref-type="bibr" rid="article-42051.r43">[43]</xref>&#x000a0;Subsequently, the group published a prospective study confirming the findings.<xref ref-type="bibr" rid="article-42051.r14">[14]</xref>&#x000a0;Neurolysis is performed after identification of trigger sites and when pain relief is more than 50% for at least 6 weeks by injecting BT. One can instill BT in the bilateral frontal, temporal, over corrugators, and occipital region (12.5 units each).<xref ref-type="bibr" rid="article-42051.r14">[14]</xref><xref ref-type="bibr" rid="article-42051.r15">[15]</xref>&#x000a0;Examination of hypertrophied nasal turbinates irritating the nasal septum should be done.</p>
        <p>
<bold>Neuromodulation</bold>
</p>
        <p>Occipital nerve stimulation (ONS) can have benefits for pain in the distribution of both occipital and trigeminal nerves through the modulatory activity of the trigeminocervical complex. This consists of the trigeminal nucleus and portions of the upper 3 cervical dorsal nerves. It can result in 30% to 50% of patients having more than 50% pain relief.<xref ref-type="bibr" rid="article-42051.r44">[44]</xref><xref ref-type="bibr" rid="article-42051.r45">[45]</xref><xref ref-type="bibr" rid="article-42051.r46">[46]</xref>&#x000a0;This procedure has high rates of lead readjustments (around 50%) but that is minimally invasive.<xref ref-type="bibr" rid="article-42051.r46">[46]</xref>&#x000a0;ONS can also help in cluster headaches.<xref ref-type="bibr" rid="article-42051.r47">[47]</xref>&#x000a0;(Level I and II)</p>
      </sec>
      <sec id="article-42051.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=42051&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=42051">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/42051/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=42051">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-42051.s13">
        <fig id="article-42051.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Flowchart for selecting patients for migraine surgery Contributed by Jitin Bajaj, MCh</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Figure__1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-42051.s14">
        <title>References</title>
        <ref id="article-42051.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <collab>Headache Classification Committee of the International Headache Society (IHS)</collab>
            <article-title>The International Classification of Headache Disorders, 3rd edition (beta version).</article-title>
            <source>Cephalalgia</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>629</fpage>
            <page-range>629-808</page-range>
            <pub-id pub-id-type="pmid">23771276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Bigal</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Freitag</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>WF</given-names>
              </name>
              <collab>AMPP Advisory Group</collab>
            </person-group>
            <article-title>Migraine prevalence, disease burden, and the need for preventive therapy.</article-title>
            <source>Neurology</source>
            <year>2007</year>
            <month>Jan</month>
            <day>30</day>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>343</fpage>
            <page-range>343-9</page-range>
            <pub-id pub-id-type="pmid">17261680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martelletti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Katsarava</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lampl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Magis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bendtsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Negro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Mitsikostas</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation.</article-title>
            <source>J Headache Pain</source>
            <year>2014</year>
            <month>Aug</month>
            <day>28</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <pub-id pub-id-type="pmid">25169882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wienecke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Fahrenkrug</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Olesen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ashina</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine.</article-title>
            <source>Cephalalgia</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>226</fpage>
            <page-range>226-36</page-range>
            <pub-id pub-id-type="pmid">18254893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kruuse</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Birk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Olesen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Migraine can be induced by sildenafil without changes in middle cerebral artery diameter.</article-title>
            <source>Brain</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>126</volume>
            <issue>Pt 1</issue>
            <fpage>241</fpage>
            <page-range>241-7</page-range>
            <pub-id pub-id-type="pmid">12477710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Welch</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>D'Andrea</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tepley</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barkley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ramadan</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>The concept of migraine as a state of central neuronal hyperexcitability.</article-title>
            <source>Neurol Clin</source>
            <year>1990</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>817</fpage>
            <page-range>817-28</page-range>
            <pub-id pub-id-type="pmid">1979655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Welch</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Nagesh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gelman</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?</article-title>
            <source>Headache</source>
            <year>2001</year>
            <season>Jul-Aug</season>
            <volume>41</volume>
            <issue>7</issue>
            <fpage>629</fpage>
            <page-range>629-37</page-range>
            <pub-id pub-id-type="pmid">11554950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parsons</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Cortical spreading depression: its role in migraine pathogenesis and possible therapeutic intervention strategies.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>410</fpage>
            <page-range>410-6</page-range>
            <pub-id pub-id-type="pmid">15361327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fusco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Andrea</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Miccich&#x000e8;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stecca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bernardini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cananzi</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Neurogenic inflammation in primary headaches.</article-title>
            <source>Neurol Sci</source>
            <year>2003</year>
            <month>May</month>
            <volume>24 Suppl 2</volume>
            <fpage>S61</fpage>
            <page-range>S61-4</page-range>
            <pub-id pub-id-type="pmid">12811594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Kolodner</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Sawyer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liberman</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers.</article-title>
            <source>Pain</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-52</page-range>
            <pub-id pub-id-type="pmid">11098098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramadan</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Gilkey</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Migraine prophylactic drugs: proof of efficacy, utilization and cost.</article-title>
            <source>Cephalalgia</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>73</fpage>
            <page-range>73-80</page-range>
            <pub-id pub-id-type="pmid">9137841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hepp</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Varon</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Gillard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Devine</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Adherence to oral migraine-preventive medications among patients with chronic migraine.</article-title>
            <source>Cephalalgia</source>
            <year>2015</year>
            <month>May</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>478</fpage>
            <page-range>478-88</page-range>
            <pub-id pub-id-type="pmid">25164920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silberstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Saper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.</article-title>
            <source>Headache</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>445</fpage>
            <page-range>445-50</page-range>
            <pub-id pub-id-type="pmid">10849039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guyuron</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tucker</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Surgical treatment of migraine headaches.</article-title>
            <source>Plast Reconstr Surg</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>109</volume>
            <issue>7</issue>
            <fpage>2183</fpage>
            <page-range>2183-9</page-range>
            <pub-id pub-id-type="pmid">12045534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jose</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nagori</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Roychoudhury</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Surgical Management of Migraine Headache.</article-title>
            <source>J Craniofac Surg</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>e106</fpage>
            <page-range>e106-e108</page-range>
            <pub-id pub-id-type="pmid">29068972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bovim</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fredriksen</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Stolt-Nielsen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sjaastad</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Neurolysis of the greater occipital nerve in cervicogenic headache. A follow up study.</article-title>
            <source>Headache</source>
            <year>1992</year>
            <month>Apr</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>175</fpage>
            <page-range>175-9</page-range>
            <pub-id pub-id-type="pmid">1582835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schoenen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ashina</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sphenopalatine ganglion neuromodulation in migraine: what is the rationale?</article-title>
            <source>Cephalalgia</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>382</fpage>
            <page-range>382-91</page-range>
            <pub-id pub-id-type="pmid">24293088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reed</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Banta</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Will</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience.</article-title>
            <source>Cephalalgia</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>260</fpage>
            <page-range>260-71</page-range>
            <pub-id pub-id-type="pmid">19732075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schoenen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vandersmissen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jeangette</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Herroelen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vandenheede</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>G&#x000e9;rard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Magis</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial.</article-title>
            <source>Neurology</source>
            <year>2013</year>
            <month>Feb</month>
            <day>19</day>
            <volume>80</volume>
            <issue>8</issue>
            <fpage>697</fpage>
            <page-range>697-704</page-range>
            <pub-id pub-id-type="pmid">23390177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mauskop</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches.</article-title>
            <source>Cephalalgia</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>82</fpage>
            <page-range>82-6</page-range>
            <pub-id pub-id-type="pmid">15658944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hord</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Mueed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adamolekun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Naritoku</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>The effect of vagus nerve stimulation on migraines.</article-title>
            <source>J Pain</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>9</issue>
            <fpage>530</fpage>
            <page-range>530-4</page-range>
            <pub-id pub-id-type="pmid">14636821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Juha</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lou</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lian</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Woralux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hugo</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Jianliang</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Trigger areas nerve decompression for refractory chronic migraine.</article-title>
            <source>Clin Neurol Neurosurg</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>206</volume>
            <fpage>106699</fpage>
            <pub-id pub-id-type="pmid">34053808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guyuron</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kriegler</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Amini</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Comprehensive surgical treatment of migraine headaches.</article-title>
            <source>Plast Reconstr Surg</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>115</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">15622223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Totonchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guyuron</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ansari</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Surgical Options for Migraine: An Overview.</article-title>
            <source>Neurol India</source>
            <year>2021</year>
            <season>Mar-Apr</season>
            <volume>69</volume>
            <issue>Supplement</issue>
            <fpage>S105</fpage>
            <page-range>S105-S109</page-range>
            <pub-id pub-id-type="pmid">34003155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin injection of eye muscles to correct strabismus.</article-title>
            <source>Trans Am Ophthalmol Soc</source>
            <year>1981</year>
            <volume>79</volume>
            <fpage>734</fpage>
            <page-range>734-70</page-range>
            <pub-id pub-id-type="pmid">7043872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erbguth</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Naumann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison".</article-title>
            <source>Neurology</source>
            <year>1999</year>
            <month>Nov</month>
            <day>10</day>
            <volume>53</volume>
            <issue>8</issue>
            <fpage>1850</fpage>
            <page-range>1850-3</page-range>
            <pub-id pub-id-type="pmid">10563638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ababneh</surname>
                <given-names>OH</given-names>
              </name>
              <name>
                <surname>Cetinkaya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kulwin</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>254</fpage>
            <page-range>254-61</page-range>
            <pub-id pub-id-type="pmid">23844601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Truong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Comella</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Ondo</surname>
                <given-names>WG</given-names>
              </name>
              <collab>Dysport Benign Essential Blepharospasm Study Group</collab>
            </person-group>
            <article-title>Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial.</article-title>
            <source>Parkinsonism Relat Disord</source>
            <year>2008</year>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>407</fpage>
            <page-range>407-14</page-range>
            <pub-id pub-id-type="pmid">18325821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsui</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Eisen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stoessl</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Calne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Calne</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Double-blind study of botulinum toxin in spasmodic torticollis.</article-title>
            <source>Lancet</source>
            <year>1986</year>
            <month>Aug</month>
            <day>02</day>
            <volume>2</volume>
            <issue>8501</issue>
            <fpage>245</fpage>
            <page-range>245-7</page-range>
            <pub-id pub-id-type="pmid">2874278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greene</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Fahn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moskowitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Flaster</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis.</article-title>
            <source>Neurology</source>
            <year>1990</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>8</issue>
            <fpage>1213</fpage>
            <page-range>1213-8</page-range>
            <pub-id pub-id-type="pmid">2199847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>1990</year>
            <month>Aug</month>
            <volume>53</volume>
            <issue>8</issue>
            <fpage>633</fpage>
            <page-range>633-9</page-range>
            <pub-id pub-id-type="pmid">2213039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brin</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Blitzer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fahn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gould</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lovelace</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Adductor laryngeal dystonia (spastic dysphonia): treatment with local injections of botulinum toxin (Botox).</article-title>
            <source>Mov Disord</source>
            <year>1989</year>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>287</fpage>
            <page-range>287-96</page-range>
            <pub-id pub-id-type="pmid">2811888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brin</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Fahn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moskowitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shale</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Blitzer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>List</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lovelace</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.</article-title>
            <source>Mov Disord</source>
            <year>1987</year>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>237</fpage>
            <page-range>237-54</page-range>
            <pub-id pub-id-type="pmid">3504553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lungu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Karp</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Alter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zolbrod</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hallett</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more.</article-title>
            <source>Mov Disord</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>750</fpage>
            <page-range>750-3</page-range>
            <pub-id pub-id-type="pmid">21506157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schnider</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Binder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Auff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kittler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wolff</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms.</article-title>
            <source>Br J Dermatol</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>136</volume>
            <issue>4</issue>
            <fpage>548</fpage>
            <page-range>548-52</page-range>
            <pub-id pub-id-type="pmid">9155956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durham</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Cady</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cady</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy.</article-title>
            <source>Headache</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-42; discussion 42-3</page-range>
            <pub-id pub-id-type="pmid">14979881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Binder</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Brin</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Blitzer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schoenrock</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Pogoda</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.</article-title>
            <source>Otolaryngol Head Neck Surg</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>123</volume>
            <issue>6</issue>
            <fpage>669</fpage>
            <page-range>669-76</page-range>
            <pub-id pub-id-type="pmid">11112955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freitag</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Urban</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.</article-title>
            <source>Headache</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>201</fpage>
            <page-range>201-9</page-range>
            <pub-id pub-id-type="pmid">18042229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vollmer-Haase</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schwaag</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rahmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Husstedt</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>Frese</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.</article-title>
            <source>Cephalalgia</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>10</issue>
            <fpage>838</fpage>
            <page-range>838-43</page-range>
            <pub-id pub-id-type="pmid">15377314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gawel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brandes</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pokta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vandenburgh</surname>
                <given-names>AM</given-names>
              </name>
              <collab>BOTOX North American Episodic Migraine Study Group</collab>
            </person-group>
            <article-title>Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.</article-title>
            <source>Headache</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>486</fpage>
            <page-range>486-99</page-range>
            <pub-id pub-id-type="pmid">17445098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cot&#x000e9;</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Polder</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Walton</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>407</fpage>
            <page-range>407-15</page-range>
            <pub-id pub-id-type="pmid">16112345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janis</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Dhanik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Validation of the peripheral trigger point theory of migraine headaches: single-surgeon experience using botulinum toxin and surgical decompression.</article-title>
            <source>Plast Reconstr Surg</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>128</volume>
            <issue>1</issue>
            <fpage>123</fpage>
            <page-range>123-131</page-range>
            <pub-id pub-id-type="pmid">21701329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guyuron</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Varghai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Michelow</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Corrugator supercilii muscle resection and migraine headaches.</article-title>
            <source>Plast Reconstr Surg</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>106</volume>
            <issue>2</issue>
            <fpage>429</fpage>
            <page-range>429-34; discussion 435-7</page-range>
            <pub-id pub-id-type="pmid">10946944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Popeney</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Al&#x000f3;</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Peripheral neurostimulation for the treatment of chronic, disabling transformed migraine.</article-title>
            <source>Headache</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>369</fpage>
            <page-range>369-75</page-range>
            <pub-id pub-id-type="pmid">12656708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saper</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>McCarville</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <collab>ONSTIM Investigators</collab>
            </person-group>
            <article-title>Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study.</article-title>
            <source>Cephalalgia</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <page-range>271-85</page-range>
            <pub-id pub-id-type="pmid">20861241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Saper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Slavin</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Sharan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Narouze</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mogilner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trentman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vaisman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ordia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Deer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Washburn</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Mekhail</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study.</article-title>
            <source>Cephalalgia</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>32</volume>
            <issue>16</issue>
            <fpage>1165</fpage>
            <page-range>1165-79</page-range>
            <pub-id pub-id-type="pmid">23034698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42051.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mueller</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Gaul</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Katsarava</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Sure</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Gasser</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Occipital nerve stimulation for the treatment of chronic cluster headache - lessons learned from 18 months experience.</article-title>
            <source>Cent Eur Neurosurg</source>
            <year>2011</year>
            <month>May</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>84</fpage>
            <page-range>84-9</page-range>
            <pub-id pub-id-type="pmid">21448856</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
